A Phase 1 interventional study of Liraglutide and Oral Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 37th largest by planned enrollment, is one of 2 that started in 2025, is one of 9 in phase 1, and was the 78th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 71 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 118th largest by planned enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2025, is one of 85 in phase 1, reaches primary completion later than 6 of the 65 other live ones, and was the 157th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants with T2D:
Treatment with:
Exclusion Criteria:
For participants without T2D:
- Glycosylated () > 6.5 percent (%) 48 millimole per mole (mmol/mol) at screening.
For participants with T2D:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive liraglutide subcutaneously.
Drug: Liraglutide
Participants will receive semaglutide orally.
Drug: Oral Semaglutide
Participants will receive semaglutide subcutaneously.
Drug: Semaglutide
Participants will receive liraglutide subcutaneously.
Participants will receive semaglutide orally.
Participants will receive semaglutide subcutaneously.
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141
Gastric volume after fasting following a solid, high-fat meal after dosing of s.c. liraglutide once daily
Measured as milliliters per kilogram (mL/kg).
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
Gastric volume after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily
Measured as mL/kg.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161
Gastric volume after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly
Measured as mL/kg.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal after dosing of s.c. liraglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal after dosing of s.c. liraglutide once daily (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 44
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 165
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 8, Day 148
Gastric volume after fasting following liquid meal after dosing of s.c. liraglutide once daily
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 44
Gastric volume after fasting following liquid meal after dosing of oral semaglutide once daily
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 165
Gastric volume after fasting following a liquid meal after dosing of s.c. semaglutide once weekly
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 8, Day 148
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal after dosing of s.c. liraglutide once daily (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 44
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 165
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 8, Day 148
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. liraglutide once daily (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 48
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 12, Day 171
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 14 days after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 13, Day 178
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 9, Day 153
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 14 days after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 10, Day 160
Gastric volume after fasting following a solid, high-fat meal 1 day after dosing of s.c. liraglutide once daily
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 48
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of oral semaglutide once daily
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 12, Day 171
Gastric volume after fasting following a solid, high-fat meal 14 days after dosing of oral semaglutide once daily
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 13, Day 178
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of s.c. semaglutide once weekly
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 9, Day 153
Gastric volume after fasting following a solid, high-fat meal 14 days after dosing of s.c. semaglutide once weekly
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 10, Day 160
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 1 day after dosing of s.c. liraglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 48
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 12, Day 171
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 14 days after dosing of oral semaglutide once daily (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 13, Day 178
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of s.c. semaglutide once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 9, Day 153
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 14 days after dosing of s.c. semaglutide 2.4 mg once weekly (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 10, Day 160
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 2, Day 1
Gastric volume after fasting following a solid, high-fat meal
Measured as mL/kg.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 2, Day 1
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 2, Day 1
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 2, Day 5
Gastric volume after fasting following a liquid meal
Measured as mL/kg
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 2, Day 5
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal (Yes/No)
Measured as count of participants.
Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 2, Day 5
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 13 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Liraglutide · Semaglutide